Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.008
Jianyun Li, C. Tu, Ling Peng, Can Huang, Xuyan Zhang, Dianwen Wang
Objective To investigate the incidence and risk factors of catheter-related venous thrombosis (PICC-DVT) after peripherally inserted central catheter (PICC) in patients with hematologic malignancies, and to analyze the safety of anti-coagulation therapy with low-molecular-weight heparin. Methods From August 2016 to June 2018, 43 patients with hematologic malignancies received PICC in Baoan District People's Hospital of Shenzhen City were enrolled. The patients were divided into low-molecular-weight heparin anticoagulation group (22 cases) and blank control group (21 cases) according to the random number table method. The blood routine, coagulation quadruple, D-dimer, protein C activity, protein S activity, and antithrombin Ⅲ activity before and after catheterization were compared between the two groups. Results Of the 43 patients, 5 cases (11.62%) occurred PICC-DVT within 1 month after PICC, including 2 cases (9.09%) in the low-molecular-weight heparin anticoagulation group, and 3 cases (14.29%) in the blank control group, the difference between the two groups was not statistically significant (P = 0.664). No pulmonary embolism occurred in all patients with PICC-DVT. One case in the blank control group developed PICC-DVT and catheter-associated staphylococcus aureus infection, the patient was extubated after anti-infection and thrombolytic therapy, the other patients with PICC-DVT were not extubated, and the thrombus was dissolved after anticoagulant therapy. There were no significant differences in the white blood cell count, platelet count, prothrombin time, activated partial thromboplastin time, D-dimer, protein C activity, protein S activity, and antithrombin Ⅲ activity between the low-molecular-weight heparin anticoagulation group and blank control group (all P > 0.05). The anticoagulant index (protein C, protein S or antithrombin Ⅲ activity) was decreased in 5 patients with PICC-DVT, and in 38 non-thrombotic patients, the anticoagulant index was reduced in 16 patients (42.11%), the difference was statistically significant (P = 0.021). Conclusions The incidence of protein C, protein S or antithrombin Ⅲ activity reduction in hematological malignancies patients with PICC-DVT is higher than that in non-thrombotic patients. Low-molecular-weight heparin anticoagulant therapy can not reduce the occurrence of PICC-DVT within 1 month after PICC in patients with hematological malignancies, but the treatment is safe and has no relevant bleeding event. Key words: Hematologic neoplasms; Peripherally inserted central catheter; Antithrombin Ⅲ; Protein C; Protein S; Catheter-related thrombus
{"title":"Study on risk factors of catheter-related venous thrombosis and prevention effect of low-molecular-weight heparin in patients with hematological malignancies","authors":"Jianyun Li, C. Tu, Ling Peng, Can Huang, Xuyan Zhang, Dianwen Wang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.008","url":null,"abstract":"Objective \u0000To investigate the incidence and risk factors of catheter-related venous thrombosis (PICC-DVT) after peripherally inserted central catheter (PICC) in patients with hematologic malignancies, and to analyze the safety of anti-coagulation therapy with low-molecular-weight heparin. \u0000 \u0000 \u0000Methods \u0000From August 2016 to June 2018, 43 patients with hematologic malignancies received PICC in Baoan District People's Hospital of Shenzhen City were enrolled. The patients were divided into low-molecular-weight heparin anticoagulation group (22 cases) and blank control group (21 cases) according to the random number table method. The blood routine, coagulation quadruple, D-dimer, protein C activity, protein S activity, and antithrombin Ⅲ activity before and after catheterization were compared between the two groups. \u0000 \u0000 \u0000Results \u0000Of the 43 patients, 5 cases (11.62%) occurred PICC-DVT within 1 month after PICC, including 2 cases (9.09%) in the low-molecular-weight heparin anticoagulation group, and 3 cases (14.29%) in the blank control group, the difference between the two groups was not statistically significant (P = 0.664). No pulmonary embolism occurred in all patients with PICC-DVT. One case in the blank control group developed PICC-DVT and catheter-associated staphylococcus aureus infection, the patient was extubated after anti-infection and thrombolytic therapy, the other patients with PICC-DVT were not extubated, and the thrombus was dissolved after anticoagulant therapy. There were no significant differences in the white blood cell count, platelet count, prothrombin time, activated partial thromboplastin time, D-dimer, protein C activity, protein S activity, and antithrombin Ⅲ activity between the low-molecular-weight heparin anticoagulation group and blank control group (all P > 0.05). The anticoagulant index (protein C, protein S or antithrombin Ⅲ activity) was decreased in 5 patients with PICC-DVT, and in 38 non-thrombotic patients, the anticoagulant index was reduced in 16 patients (42.11%), the difference was statistically significant (P = 0.021). \u0000 \u0000 \u0000Conclusions \u0000The incidence of protein C, protein S or antithrombin Ⅲ activity reduction in hematological malignancies patients with PICC-DVT is higher than that in non-thrombotic patients. Low-molecular-weight heparin anticoagulant therapy can not reduce the occurrence of PICC-DVT within 1 month after PICC in patients with hematological malignancies, but the treatment is safe and has no relevant bleeding event. \u0000 \u0000 \u0000Key words: \u0000Hematologic neoplasms; Peripherally inserted central catheter; Antithrombin Ⅲ; Protein C; Protein S; Catheter-related thrombus","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43543766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.015
F. Ye
Cancer-related anemia (CRA) is a complication of tumor patients in the development and treatment of diseases. Studies have shown that the incidence of anemia in non-hematologic malignancies is about 40%, and the incidence can reach 54% during tumor radiotherapy and chemotherapy. The pathogenesis of CRA has not been fully clarified, and studies at home and abroad are also very limited. The quality of life and prognosis of CRA patients are poor. In China, due to the imbalance of economic level and the development of medical conditions, doctors in different levels of medical units have different levels of understanding and attention to CRA. Therefore, it is particularly important to strengthen the standardized diagnosis and treatment of CRA. The effectiveness and safety of the presently accepted therapeutic approaches are defined. The new treatment methods are still in the research stage. The article reviews the status of diagnosis and treatment of CRA. Key words: Neoplasms; Anemia; Pathogenesis; Treatment
{"title":"Treatment progress of cancer-related anemia","authors":"F. Ye","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.015","url":null,"abstract":"Cancer-related anemia (CRA) is a complication of tumor patients in the development and treatment of diseases. Studies have shown that the incidence of anemia in non-hematologic malignancies is about 40%, and the incidence can reach 54% during tumor radiotherapy and chemotherapy. The pathogenesis of CRA has not been fully clarified, and studies at home and abroad are also very limited. The quality of life and prognosis of CRA patients are poor. In China, due to the imbalance of economic level and the development of medical conditions, doctors in different levels of medical units have different levels of understanding and attention to CRA. Therefore, it is particularly important to strengthen the standardized diagnosis and treatment of CRA. The effectiveness and safety of the presently accepted therapeutic approaches are defined. The new treatment methods are still in the research stage. The article reviews the status of diagnosis and treatment of CRA. \u0000 \u0000 \u0000Key words: \u0000Neoplasms; Anemia; Pathogenesis; Treatment","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45000447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Value of different b values of diffusion-weighted imaging in the differential diagnosis of benign and malignant tumors","authors":"Tao Yue, S. Zhao, X. Du","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.014","url":null,"abstract":"目的 \u0000探讨良恶性肿瘤组织磁共振成像（MRI）不同扩散敏感系数（b值）信号值的差异。 \u0000 \u0000 \u0000方法 \u0000收集2018年1月至2018年6月在山西省中医院就诊的恶性肿瘤患者36例，同时收集良性肿瘤患者29例，进行影像学和病理诊断。应用多重线性回归模型对性别、年龄变量进行控制后，分析良性、恶性肿瘤在不同b值下信号值变化量的差异。 \u0000 \u0000 \u0000结果 \u0000不同b值下，恶性肿瘤组织均呈高信号，信号强度高于良性肿瘤组织（F值分别为7.779、8.516和13.820，均P<0.05）；恶性肿瘤组织b值600 s/mm2~1 000 s/mm2以及800 s/mm2~1 000 s/mm2的信号值变化百分比[（26.83±8.53）%、（5.91±9.54）%]低于良性肿瘤组织[（43.89±14.55）%、（18.74±10.28）%]，差异均具有统计学意义（F值分别为33.354和26.330，均P<0.05）。多因素分析显示，在控制了性别和年龄变量后，b值由600 s/mm2变为1 000 s/mm2时，回归方程校正系数为-18.43（-24.42~-12.44），即相对于良性肿瘤，恶性肿瘤信号强度平均少衰减18.43%（F=15.635，P<0.05）；b值由800 s/mm2变为1 000 s/mm2时，回归方程校正系数为-13.81（-19.02~-8.42），即相对于良性肿瘤，恶性肿瘤信号强度平均少衰减13.81%（F=9.172，P<0.05）。 \u0000 \u0000 \u0000结论 \u0000临床肿瘤影像学辅助诊断中，不仅要参考表观扩散系数值，也应对不同b值所测的信号值的变化进行比较，以达到更好的辅助诊断效果。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41554236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.002
Meng Tong, Lixin Sun
Objective To explore the diagnostic value of combined detection of serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) for ovarian epithelial cancer. Methods Patients who underwent surgery for the adnexal tumor at Shanxi Provincial Cancer Hospital from January 2012 to December 2017 were enrolled. According to the postoperative pathological results, these patients were divided into the ovarian epithelial cancer group (494 cases) and benign ovarian disease group (462 cases). The serum expressions of HE4 and CA125 in the two groups were detected by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay. The diagnostic value of detection of HE4 and CA125 alone or in combination for ovarian epithelial cancer was analyzed. Results The median levels (P 25 - P 75) of serum CA125 and HE4 in ovarian epithelial cancer group were 273.34 U/ml (39.34 U/ml, 709.74 U/ml) and 199.08 pmol/L (75.81 pmol/L, 449.20 pmol/L), which were higher than those in ovarian benign disease group [16.30 U/ml (6.30 U/ml, 53.60 U/ml) and 39.54 pmol/L (29.57 pmol/L, 53.80 pmol/L)] (both P < 0.05). There was a positive correlation between serum CA125 and HE4 levels in ovarian epithelial cancer group (r = 0.481, P < 0.01). Serum CA125 and HE4 levels in patients with stage Ⅲ and Ⅳ were higher than those in patients with stage Ⅰ and Ⅱ (both P < 0.05), and serum CA125 and HE4 levels in patients with poor differentiation were higher than those in patients with moderate differentiation (P < 0.05). Compared with CA125, the specificity and positive predictive value of serum HE4 for the diagnosis of ovarian epithelial cancer were higher (both P < 0.01). Compared with HE4 alone, the sensitivity of CA125 combined with HE4 increased (P = 0.004) and the specificity decreased (P = 0.044). When both CA125 and HE4 were positive for positive results, compared with HE4 alone, the specificity and positive predictive value increased (both P < 0.01), but the sensitivity decreased (both P < 0.01). In patients with CA125+ HE4-, the sensitivity and specificity decreased, while in CA125- HE4+ patients, the specificity was elevated, but the difference was not statistically significant (P = 0.892). When one of CA125 and HE4 was positive for positive results, the sensitivity and negative predictive value increased (both P < 0.01), but the specificity and positive predictive value decreased (both P < 0.01). The area under the curve of serum CA125 and HE4 combined detection was 0.911, indicating its clinical diagnostic value was better than that of the two alone. Conclusions In the diagnosis of epithelial ovarian cancer, the specificity of serum HE4 is higher than that of CA125, but the sensitivity is lower than that of CA125. The combined detection of HE4 and CA125 is more conducive to improve the diagnostic accuracy of ovarian epithelial cancer. Key words: Ovarian neoplasms; Carbohydrate antigen 125; Human epididymis protein 4; Diagnosis
{"title":"Diagnostic value of combined detection of carbohydrate antigen 125 and human epididymis protein 4 for epithelial ovarian cancer","authors":"Meng Tong, Lixin Sun","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.002","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.002","url":null,"abstract":"Objective \u0000To explore the diagnostic value of combined detection of serum human epididymis protein 4 (HE4) and carbohydrate antigen 125 (CA125) for ovarian epithelial cancer. \u0000 \u0000 \u0000Methods \u0000Patients who underwent surgery for the adnexal tumor at Shanxi Provincial Cancer Hospital from January 2012 to December 2017 were enrolled. According to the postoperative pathological results, these patients were divided into the ovarian epithelial cancer group (494 cases) and benign ovarian disease group (462 cases). The serum expressions of HE4 and CA125 in the two groups were detected by enzyme-linked immunosorbent assay (ELISA) and chemiluminescence immunoassay. The diagnostic value of detection of HE4 and CA125 alone or in combination for ovarian epithelial cancer was analyzed. \u0000 \u0000 \u0000Results \u0000The median levels (P 25 - P 75) of serum CA125 and HE4 in ovarian epithelial cancer group were 273.34 U/ml (39.34 U/ml, 709.74 U/ml) and 199.08 pmol/L (75.81 pmol/L, 449.20 pmol/L), which were higher than those in ovarian benign disease group [16.30 U/ml (6.30 U/ml, 53.60 U/ml) and 39.54 pmol/L (29.57 pmol/L, 53.80 pmol/L)] (both P < 0.05). There was a positive correlation between serum CA125 and HE4 levels in ovarian epithelial cancer group (r = 0.481, P < 0.01). Serum CA125 and HE4 levels in patients with stage Ⅲ and Ⅳ were higher than those in patients with stage Ⅰ and Ⅱ (both P < 0.05), and serum CA125 and HE4 levels in patients with poor differentiation were higher than those in patients with moderate differentiation (P < 0.05). Compared with CA125, the specificity and positive predictive value of serum HE4 for the diagnosis of ovarian epithelial cancer were higher (both P < 0.01). Compared with HE4 alone, the sensitivity of CA125 combined with HE4 increased (P = 0.004) and the specificity decreased (P = 0.044). When both CA125 and HE4 were positive for positive results, compared with HE4 alone, the specificity and positive predictive value increased (both P < 0.01), but the sensitivity decreased (both P < 0.01). In patients with CA125+ HE4-, the sensitivity and specificity decreased, while in CA125- HE4+ patients, the specificity was elevated, but the difference was not statistically significant (P = 0.892). When one of CA125 and HE4 was positive for positive results, the sensitivity and negative predictive value increased (both P < 0.01), but the specificity and positive predictive value decreased (both P < 0.01). The area under the curve of serum CA125 and HE4 combined detection was 0.911, indicating its clinical diagnostic value was better than that of the two alone. \u0000 \u0000 \u0000Conclusions \u0000In the diagnosis of epithelial ovarian cancer, the specificity of serum HE4 is higher than that of CA125, but the sensitivity is lower than that of CA125. The combined detection of HE4 and CA125 is more conducive to improve the diagnostic accuracy of ovarian epithelial cancer. \u0000 \u0000 \u0000Key words: \u0000Ovarian neoplasms; Carbohydrate antigen 125; Human epididymis protein 4; Diagnosis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42922138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.009
Jun Wang, Zhuangzhuang Wu, Z. Lyu
Objective To investigate the survival of patients with osteosarcoma treated in a single institute. Methods A total of 44 patients with osteosarcoma who had undergone surgical treatment in the Second Hospital of Shanxi Medical University from January 2013 to January 2018 were enrolled in this retrospective study. After the diagnosis of osteosarcoma, patients received cisplatin plus doxorubicin neoadjuvant chemotherapy. The patient's basic data, auxiliary examination results, surgical methods, pathological reports, prognosis and other information were reviewed and recorded, and the Kaplan-Meier method, Cox regression model were used to analyze the relationship between various factors and prognosis of patients. Results Among 44 patients, there were 23 males and 21 females, aged from 7 to 62 years old (average 27.2 years old); the tumor site of 5 cases was located at the upper limbs and 39 was located at the lower limbs; the diameter of the tumor was < 10 cm in 30 cases, ≥10 cm in 14 cases. All patients underwent extensive resection, including 35 cases of limb salvage surgery and 9 cases of amputation. At the end of follow-up, the 3-year overall survival rate was 65.5%. The 3-year overall survival rates in patients with or without local recurrence were 40.0% and 72.4%, respectively (P = 0.037). The 3-year overall survival rates in patients with or without lung metastasis were 32.0% and 84.5%, respectively (P < 0.01). The 3-year overall survival rates in patients with tumor's diameter≥10 cm or <10 cm were 40.2% and 78.1%, respectively (P = 0.003). The 3-year overall survival rates in patients with or without standard chemotherapy were 74.9% and 35.8%, respectively (P = 0.048). The 3-year overall survival rates in patients with high or normal lactate dehydrogenase at the time of diagnosis were 38.1% and 72.3%, respectively (P = 0.010). Multivariate analysis showed that standard chemotherapy (P = 0.005) and lung metastasis (P = 0.003) were independent prognostic factors affecting the survival of patients with osteosarcoma. Conclusions Neoadjuvant chemotherapy combined with surgical methods can improve the survival rate of patients with osteosarcoma of the extremities. Nonstandard chemotherapy and lung metastasis during or after treatment affect the survival of patients with osteosarcoma. Key words: Osteosarcoma; Chemotherapy, adjuvant; Prognosis; Neoplasm metastasis
{"title":"Prognosis analysis of 44 patients with extremity osteosarcoma","authors":"Jun Wang, Zhuangzhuang Wu, Z. Lyu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.009","url":null,"abstract":"Objective \u0000To investigate the survival of patients with osteosarcoma treated in a single institute. \u0000 \u0000 \u0000Methods \u0000A total of 44 patients with osteosarcoma who had undergone surgical treatment in the Second Hospital of Shanxi Medical University from January 2013 to January 2018 were enrolled in this retrospective study. After the diagnosis of osteosarcoma, patients received cisplatin plus doxorubicin neoadjuvant chemotherapy. The patient's basic data, auxiliary examination results, surgical methods, pathological reports, prognosis and other information were reviewed and recorded, and the Kaplan-Meier method, Cox regression model were used to analyze the relationship between various factors and prognosis of patients. \u0000 \u0000 \u0000Results \u0000Among 44 patients, there were 23 males and 21 females, aged from 7 to 62 years old (average 27.2 years old); the tumor site of 5 cases was located at the upper limbs and 39 was located at the lower limbs; the diameter of the tumor was < 10 cm in 30 cases, ≥10 cm in 14 cases. All patients underwent extensive resection, including 35 cases of limb salvage surgery and 9 cases of amputation. At the end of follow-up, the 3-year overall survival rate was 65.5%. The 3-year overall survival rates in patients with or without local recurrence were 40.0% and 72.4%, respectively (P = 0.037). The 3-year overall survival rates in patients with or without lung metastasis were 32.0% and 84.5%, respectively (P < 0.01). The 3-year overall survival rates in patients with tumor's diameter≥10 cm or <10 cm were 40.2% and 78.1%, respectively (P = 0.003). The 3-year overall survival rates in patients with or without standard chemotherapy were 74.9% and 35.8%, respectively (P = 0.048). The 3-year overall survival rates in patients with high or normal lactate dehydrogenase at the time of diagnosis were 38.1% and 72.3%, respectively (P = 0.010). Multivariate analysis showed that standard chemotherapy (P = 0.005) and lung metastasis (P = 0.003) were independent prognostic factors affecting the survival of patients with osteosarcoma. \u0000 \u0000 \u0000Conclusions \u0000Neoadjuvant chemotherapy combined with surgical methods can improve the survival rate of patients with osteosarcoma of the extremities. Nonstandard chemotherapy and lung metastasis during or after treatment affect the survival of patients with osteosarcoma. \u0000 \u0000 \u0000Key words: \u0000Osteosarcoma; Chemotherapy, adjuvant; Prognosis; Neoplasm metastasis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46150301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.018
Hailing Ning
Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL. Key words: Lymphoma, follicular; Chimeric antigen receptor T-cell; CD19; Anti-CD20 monoclonal antibody
{"title":"Progress of chimeric antigen receptor T-cell for treatment of follicular lymphoma","authors":"Hailing Ning","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.018","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.018","url":null,"abstract":"Follicular lymphoma (FL) is usually occult, with a wide range of disease manifestations and prognosis. In recent years, with the combination of anti-CD20 monoclonal antibody and standard chemotherapy methods, as well as the use of immunomodulators and hematopoietic stem cell transplantation, the survival rate of FL patients has been greatly improved, but it is still considered to be an incurable disease. Recent studies have shown that the chimeric antigen receptor T-cell (CAR-T) therapy can improve the survival rate and the prognosis of FL patients. The article will elaborate on the mechanism, clinical research progress, adverse reactions and limitations of CAR-T in the treatment of FL. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, follicular; Chimeric antigen receptor T-cell; CD19; Anti-CD20 monoclonal antibody","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49145267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.003
Weimin Du, Yumin Zhang, Xueying Tan, Xiaona Xu, Ping Zhang
Objective To investigate the expression of integrin α5 in cervical cancer, and to explore its relationship with clinicopathological characteristics of patients with cervical cancer. Methods Immunohistochemistry was used to detect the expression of integrin α 5 in cervical cancer tissues of 60 cases and normal cervical paraffin-embeded tissues of 20 cases of benign uterine lesions undergoing hysterectomy from Qingdao Municipal Hospital between January 2014 and December 2017. Real-time quantitative polymerase chain reaction (RT-PCR) was used to detect the mRNA expression level of integrin α5 in 20 fresh cervical cancer tissues and 20 normal cervical tissues collected from benign cervical lesions in Qingdao Municipal Hospital between January 2018 and July 2018. The relationship between the expression of integrin α5 and the clinicopathological characteristics of patients with cervical cancer was analyzed. Results The positive expression rate of integrin α5 protein in cervical cancer and normal cervical tissues was 63.3% (38/60), 35.0% (7/20), respectively, and the difference was statistically significant (χ2 = 4.893, P < 0.05). The expression of integrin α5 mRNA in cervical cancer was 1.6±0.4 times as high as that in normal cervical tissues (t = 5.529, P < 0.01). The positive expression of integrin α5 protein was associated with lymph node metastasis in cervical cancer patients (Z = -2.636, P = 0.008). Conclusion The high expression of integrin α5 is related to lymph node metastasis of cervical cancer, and integrin α5 may be a new potential target for treatment of cervical cancer. Key words: Uterine cervical neoplasms; Integrin alpha 5; Lymph node metastasis
目的探讨整合素α5在宫颈癌中的表达，并探讨其与宫颈癌患者临床病理特征的关系。方法采用免疫组织化学方法检测整合素α 5在青岛市属医院2014年1月至2017年12月间60例宫颈癌组织和20例良性子宫病变行子宫切除术的正常宫颈石蜡包埋组织中的表达。采用实时定量聚合酶链反应(RT-PCR)检测2018年1月至2018年7月青岛市市属医院采集的20例宫颈良性病变患者新鲜宫颈癌组织和20例正常宫颈组织中整合素α5 mRNA表达水平。分析整合素α5的表达与宫颈癌患者临床病理特征的关系。结果整合素α5蛋白在宫颈癌与正常宫颈组织中的阳性表达率分别为63.3%(38/60)、35.0%(7/20)，差异有统计学意义(χ2 = 4.893, P < 0.05)。整合素α5 mRNA在宫颈癌组织中的表达是宫颈正常组织的1.6±0.4倍(t = 5.529, P < 0.01)。整合素α5蛋白阳性表达与宫颈癌患者淋巴结转移相关(Z = -2.636, P = 0.008)。结论整合素α5的高表达与宫颈癌淋巴结转移有关，整合素α5可能是治疗宫颈癌的一个新的潜在靶点。关键词:子宫颈肿瘤;整合素α 5;淋巴结转移
{"title":"Expression of integrin α5 in cervical cancer and its significance","authors":"Weimin Du, Yumin Zhang, Xueying Tan, Xiaona Xu, Ping Zhang","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.003","url":null,"abstract":"Objective \u0000To investigate the expression of integrin α5 in cervical cancer, and to explore its relationship with clinicopathological characteristics of patients with cervical cancer. \u0000 \u0000 \u0000Methods \u0000Immunohistochemistry was used to detect the expression of integrin α 5 in cervical cancer tissues of 60 cases and normal cervical paraffin-embeded tissues of 20 cases of benign uterine lesions undergoing hysterectomy from Qingdao Municipal Hospital between January 2014 and December 2017. Real-time quantitative polymerase chain reaction (RT-PCR) was used to detect the mRNA expression level of integrin α5 in 20 fresh cervical cancer tissues and 20 normal cervical tissues collected from benign cervical lesions in Qingdao Municipal Hospital between January 2018 and July 2018. The relationship between the expression of integrin α5 and the clinicopathological characteristics of patients with cervical cancer was analyzed. \u0000 \u0000 \u0000Results \u0000The positive expression rate of integrin α5 protein in cervical cancer and normal cervical tissues was 63.3% (38/60), 35.0% (7/20), respectively, and the difference was statistically significant (χ2 = 4.893, P < 0.05). The expression of integrin α5 mRNA in cervical cancer was 1.6±0.4 times as high as that in normal cervical tissues (t = 5.529, P < 0.01). The positive expression of integrin α5 protein was associated with lymph node metastasis in cervical cancer patients (Z = -2.636, P = 0.008). \u0000 \u0000 \u0000Conclusion \u0000The high expression of integrin α5 is related to lymph node metastasis of cervical cancer, and integrin α5 may be a new potential target for treatment of cervical cancer. \u0000 \u0000 \u0000Key words: \u0000Uterine cervical neoplasms; Integrin alpha 5; Lymph node metastasis","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45373496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To explore the clinical feasibility of successfully reusing similar drugs after the improvement of interstitial pneumonia (ILD) caused by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Method: A retrospective analysis was conducted on the clinical data of a lung adenocarcinoma patient treated with gefitinib and successfully treated with similar drugs after improvement in ILD at Beijing Tsinghua Changgeng Hospital, and literature review was conducted. The result was a 53 year old male patient who developed wheezing after 50 days of treatment with gefitinib for metastatic lung adenocarcinoma. Combined with lung CT and blood gas analysis, the diagnosis was EGFR-TKI related ILD. Targeted drugs were discontinued and hormone therapy was given. After significant improvement in symptoms, similar drugs were administered again, and the tumor was controlled without any further occurrence of ILD. Conclusion: After the improvement of ILD symptoms caused by EGFR-TKI, with the patient's informed consent and close monitoring, similar drugs can be tried again in clinical practice, which can prolong the patient's survival period.
{"title":"Epidermal growth factor receptor tyrosine kinase inhibitor rechallenge after epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease: report of one case and review of literature","authors":"Fan Yu, Yanying Wang, Yuehua Huang, Xinquan Li","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.012","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.012","url":null,"abstract":"目的 \u0000探索表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI）致间质性肺炎（ILD）好转后成功再用同类药物的临床可行性。 \u0000 \u0000 \u0000方法 \u0000回顾性分析北京清华长庚医院1例肺腺癌患者应用吉非替尼致ILD治疗好转后成功再用同类药物的临床资料，并进行文献复习。 \u0000 \u0000 \u0000结果 \u0000该例为53岁男性患者，因转移性肺腺癌应用吉非替尼治疗50 d后出现喘憋，结合肺部CT及血气分析结果诊断为EGFR-TKI相关ILD，停用靶向药物并予激素治疗。症状明显改善后再次应用同类药物，肿瘤得到控制且未再发生ILD。 \u0000 \u0000 \u0000结论 \u0000EGFR-TKI致ILD症状好转后，在取得患者知情同意并密切监测的情况下，临床可尝试再用同类药物，可延长患者生存期。","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47089116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.007
Haifeng Gao, Qiujian Zhao, Ziying Gao, N. Ma
Objective To investigate the diagnostic value of ultrasound-guided fine-needle aspiration cytology (FNAC) and fine-needle aspiration washout fluid thyroglobulin (FNA-Tg) detection for neck lymph nodes metastasis in patients with papillary thyroid carcinoma (PTC). Methods A total of 214 PTC patients confirmed by pathology biopsy in Baoji Central Hospital from August 2015 to October 2018 were collected, and they all underwent ultrasound-guided FNAC, and FNA-Tg was measured by using electrochemiluminescence immunoassay. The histopathologic detection was performed for all suspicious lymph nodes after lymphadenectomy, and the results were analyzed by using statistics. Results There were 282 suspicious enlarged lymph nodes detected from 214 PTC patients. Histopathological examination showed 220 lymph node metastases were positive, 62 were negative. FNAC examination showed 193 lymph nodes were positive and 89 were negative. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of FNAC for diagnosing the lymph nodes of metastasis PTC was 84.55%, 88.71%, 73.26%, 96.37%, 61.80%, 85.46%, respectively. FNA-Tg test showed that 198 lymph nodes were diagnosed as positive metastasis and 84 were negative metastasis. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of FNA-Tg for diagnosing the lymph nodes of metastasis PTC was 88.64%, 95.16%, 83.80%, 98.48%, 70.24%, 90.07%, respectively. Both FNAC and FNA-Tg test showed 215 lymph nodes were diagnosed as positive metastasis and 76 were negative metastasis. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of combined treatments were 97.63%, 87.32%, 84.95%, 95.81%, 92.54%, 96.81%, respectively. The sensitivity and accuracy of combined detection were higher than those of single detection, and there were statistically significant differences (all P < 0.05). Conclusions FNAC and FNA-Tg detection are simple, safe and accurate. The combined detection of FNAC and FNA-Tg can improve the sensitivity and accuracy for the diagnosis of PTC lymph node metastasis. Key words: Thyroid neoplasms; Carcinoma, papillary; Lymph nodes metastasis; Biopsy, fine-needle; Washout fluid; Thyroglobulin
{"title":"Diagnostic value of ultrasound-guided fine-needle aspiration cytology and thyroglobulin detection in aspiration washout fluid for neck lymph nodes metastasis in patients with papillary thyroid carcinoma","authors":"Haifeng Gao, Qiujian Zhao, Ziying Gao, N. Ma","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.007","url":null,"abstract":"Objective \u0000To investigate the diagnostic value of ultrasound-guided fine-needle aspiration cytology (FNAC) and fine-needle aspiration washout fluid thyroglobulin (FNA-Tg) detection for neck lymph nodes metastasis in patients with papillary thyroid carcinoma (PTC). \u0000 \u0000 \u0000Methods \u0000A total of 214 PTC patients confirmed by pathology biopsy in Baoji Central Hospital from August 2015 to October 2018 were collected, and they all underwent ultrasound-guided FNAC, and FNA-Tg was measured by using electrochemiluminescence immunoassay. The histopathologic detection was performed for all suspicious lymph nodes after lymphadenectomy, and the results were analyzed by using statistics. \u0000 \u0000 \u0000Results \u0000There were 282 suspicious enlarged lymph nodes detected from 214 PTC patients. Histopathological examination showed 220 lymph node metastases were positive, 62 were negative. FNAC examination showed 193 lymph nodes were positive and 89 were negative. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of FNAC for diagnosing the lymph nodes of metastasis PTC was 84.55%, 88.71%, 73.26%, 96.37%, 61.80%, 85.46%, respectively. FNA-Tg test showed that 198 lymph nodes were diagnosed as positive metastasis and 84 were negative metastasis. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of FNA-Tg for diagnosing the lymph nodes of metastasis PTC was 88.64%, 95.16%, 83.80%, 98.48%, 70.24%, 90.07%, respectively. Both FNAC and FNA-Tg test showed 215 lymph nodes were diagnosed as positive metastasis and 76 were negative metastasis. The sensitivity, specificity, Youden index, positive predictive value, negative predictive value, accuracy of combined treatments were 97.63%, 87.32%, 84.95%, 95.81%, 92.54%, 96.81%, respectively. The sensitivity and accuracy of combined detection were higher than those of single detection, and there were statistically significant differences (all P < 0.05). \u0000 \u0000 \u0000Conclusions \u0000FNAC and FNA-Tg detection are simple, safe and accurate. The combined detection of FNAC and FNA-Tg can improve the sensitivity and accuracy for the diagnosis of PTC lymph node metastasis. \u0000 \u0000 \u0000Key words: \u0000Thyroid neoplasms; Carcinoma, papillary; Lymph nodes metastasis; Biopsy, fine-needle; Washout fluid; Thyroglobulin","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47550976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-10-28DOI: 10.3760/CMA.J.ISSN.1006-9801.2019.10.004
P. Peng, Chaohua Hu, Han Yuntao, Xu Yuanbing, Haoyuan Shen, Youlin Yu, Hongzhong Zhou
Objective To study the mRNA expressions of various CD97 isoforms in colorectal carcinoma tissues and their clinical significances. Methods A total of 50 colon cancer patients in the First Affiliated Hospital of Wenzhou Medical University from December 2013 to May 2014 and human colon cancer cell lines SW480 and SW620 were enrolled. The real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of CD97 human epidermal growth factor (EGF) (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in colon cancer tissues, adjacent tissues, normal colon tissues, SW480 cells and SW620 cells. The relationship between the mRNA expression of CD97EGF (1, 2, 5) and the clinicopathological factors was analyzed. Results Compared with those low expressions in adjacent tissues and normal tissues, the mRNA expressions of CD97 isoforms CD97EGF (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in cancer tissues were highest, and the differences were statistically significant (0.71±0.20 vs. 0.40±0.09 vs. 0.35±0.07, F = 107.642, P < 0.01; 0.45±0.11 vs. 0.26±0.05 vs. 0.27±0.06, F = 94.231, P < 0.01; 0.41±0.10 vs. 0.21±0.05 vs. 0.19±0.03, F = 165.672, P < 0.01). In addition, the mRNA expression of CD97EGF (1, 2, 5) in colon cancer patients was associated with tumor infiltration depth (T1-T2 and T3-T4), clinical stages (Ⅰ-Ⅱ and Ⅲ-Ⅳ), and the differences were statistically significant (t = -2.582, P = 0.013; t = -5.062, P < 0.01). The mRNA expression of CD97EGF (1, 2, 5) in SW620 cells was higher than that in SW480 cells. Conclusions CD97 isoforms are highly expressed in colon cancer tissues, and CD97EGF (1, 2, 5) may play an important role in the development and invasion of colon cancer. The CD97 isoforms may be new markers in the treatment of colon cancer. Key words: Colonic neoplasms; Isoform, CD97; Reverse transcriptase polymerase chain reaction; Pathology, clinical
目的研究CD97不同亚型mRNA在结直肠癌组织中的表达及其临床意义。方法选取2013年12月至2014年5月温州医科大学附属第一医院结肠癌患者50例，采用人结肠癌细胞系SW480和SW620。采用实时荧光定量聚合酶链反应(qRT-PCR)检测CD97人表皮生长因子(EGF)(1,2,5)、CD97EGF(1,2,3,5)和CD97EGF(1,2,3,4,5)在结肠癌组织、癌旁组织、正常结肠组织、SW480细胞和SW620细胞中的mRNA表达。分析CD97EGF (1,2,5) mRNA表达与临床病理因素的关系。结果CD97亚型CD97EGF(1、2、5)、CD97EGF(1、2、3、5)和CD97EGF(1、2、3、5)mRNA在癌组织中表达量最高，差异有统计学意义(0.71±0.20 vs. 0.40±0.09 vs. 0.35±0.07,F = 107.642, P < 0.01;0.45±0.11 vs. 0.26±0.05 vs. 0.27±0.06,F = 94.231, P < 0.01;0.41±0.10和0.21±0.05和0.19±0.03,F = 165.672, P < 0.01)。此外，CD97EGF (1,2,5) mRNA在结肠癌患者中的表达与肿瘤浸润深度(T1-T2和T3-T4)、临床分期(Ⅰ-Ⅱ和Ⅲ-Ⅳ)相关，差异均有统计学意义(t = -2.582, P = 0.013;t = -5.062, P < 0.01)。CD97EGF (1,2,5) mRNA在SW620细胞中的表达高于SW480细胞。结论CD97亚型在结肠癌组织中高表达，CD97EGF(1,2,5)可能在结肠癌的发生和侵袭过程中发挥重要作用。CD97亚型可能是结肠癌治疗的新标志物。关键词:结肠肿瘤;CD97同种型;逆转录酶聚合酶链反应;病理、临床
{"title":"Expressions of CD97 isoforms in colon cancer tissues and their clinical significances","authors":"P. Peng, Chaohua Hu, Han Yuntao, Xu Yuanbing, Haoyuan Shen, Youlin Yu, Hongzhong Zhou","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.10.004","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.10.004","url":null,"abstract":"Objective \u0000To study the mRNA expressions of various CD97 isoforms in colorectal carcinoma tissues and their clinical significances. \u0000 \u0000 \u0000Methods \u0000A total of 50 colon cancer patients in the First Affiliated Hospital of Wenzhou Medical University from December 2013 to May 2014 and human colon cancer cell lines SW480 and SW620 were enrolled. The real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) was used to detect the mRNA expressions of CD97 human epidermal growth factor (EGF) (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in colon cancer tissues, adjacent tissues, normal colon tissues, SW480 cells and SW620 cells. The relationship between the mRNA expression of CD97EGF (1, 2, 5) and the clinicopathological factors was analyzed. \u0000 \u0000 \u0000Results \u0000Compared with those low expressions in adjacent tissues and normal tissues, the mRNA expressions of CD97 isoforms CD97EGF (1, 2, 5), CD97EGF (1, 2, 3, 5) and CD97EGF (1, 2, 3, 4, 5) in cancer tissues were highest, and the differences were statistically significant (0.71±0.20 vs. 0.40±0.09 vs. 0.35±0.07, F = 107.642, P < 0.01; 0.45±0.11 vs. 0.26±0.05 vs. 0.27±0.06, F = 94.231, P < 0.01; 0.41±0.10 vs. 0.21±0.05 vs. 0.19±0.03, F = 165.672, P < 0.01). In addition, the mRNA expression of CD97EGF (1, 2, 5) in colon cancer patients was associated with tumor infiltration depth (T1-T2 and T3-T4), clinical stages (Ⅰ-Ⅱ and Ⅲ-Ⅳ), and the differences were statistically significant (t = -2.582, P = 0.013; t = -5.062, P < 0.01). The mRNA expression of CD97EGF (1, 2, 5) in SW620 cells was higher than that in SW480 cells. \u0000 \u0000 \u0000Conclusions \u0000CD97 isoforms are highly expressed in colon cancer tissues, and CD97EGF (1, 2, 5) may play an important role in the development and invasion of colon cancer. The CD97 isoforms may be new markers in the treatment of colon cancer. \u0000 \u0000 \u0000Key words: \u0000Colonic neoplasms; Isoform, CD97; Reverse transcriptase polymerase chain reaction; Pathology, clinical","PeriodicalId":9505,"journal":{"name":"Cancer Research and Clinic","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2019-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47079573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：